title: Central-type primitive neuroectodermal tumor of the uterus: Case report of remission of stage IV disease using adjuvant cisplatin/etoposide/bevacizumab chemotherapy and review of the literature.
abstract: •Bevacizumab was an effective agent in one case of advanced uterine PNET.•VEGF was expressed by the tumor, supporting a mechanism for effectiveness.•Cisplatin/etoposide/bevacizumab should be further studied in clinical trials.•Patient remains disease-free forty-eight months following intervention.
authors.affiliation: Rush University Medical Center, Department of Pathology, 1653 West Congress Parkway, 570 Jelke, Chicago, IL 60612, United States.
authors.forename: Jorge
authors.initials: J
authors.lastname: Novo
authors.affiliation: Rush University Medical Center, Department of Pathology, 1653 West Congress Parkway, 570 Jelke, Chicago, IL 60612, United States.
authors.forename: Pincas
authors.initials: P
authors.lastname: Bitterman
authors.affiliation: Gynecologic Cancer Institute of Chicago, 5716 W 95th Street, Oak Lawn, IL 60453, United States.
authors.forename: Alfred
authors.initials: A
authors.lastname: Guirguis
keywords: Bevacizumab; Central-type PNET; Primitive neuroectodermal tumor; Uterine PNET; Uterine neoplasm; cPNET